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Abstract—Biotechnology and intellectual property are two 
areas that have played a significant role in the transformation of 
research. Intellectual property is generally regarded as an 
important driver of innovation in science and technology, as it 
allows researchers, institutions, and inventors to recover their 
investments during the period of monopoly rights. The patent 
system encourages innovation by providing patent protection to 
inventions as well as distributing useful information. Researchers 
at universities increased their use of patents as sources of 
information and as a significant tool contributing to the economic 
progress of society. Patents have become as important as scientific 
papers, especially when assessing the impact of research on society 
and the economy. Since today it is expected from the Universities 
not only to engage in research and teaching but also to make 
money from the knowledge produced. From the collaboration of 
research institutions and interested companies, Spinoff companies 
have been formed, as a form of connecting academic researchers 
and the private sector. New ways of promoting inventions are fully 
in line with the patent protection system. Therefore, patent law is 
a key factor in the development of innovative technology and 
provides investment in further research that is imperative of 
modern societies.    
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I.  INTRODUCTION 
The patent system protects the inventor from economic 
failure by granting intellectual property rights to the inventor. 
This is achieved by allowing the inventor to prohibit the 
manufacture, use or sale of the protected invention for other 
persons over a period of time. These exclusive rights are 
granted only for a limited period of time. In Europe, this period 
is 20 years from the date of application. Furthermore, rights 
could be granted only for a geographically restricted territory or 
some specific country. European patents can be granted for up 
to 38 countries (signatories to the European Patent Convention), 
but it should be subsequently validated in each country in which 
the patent owner seeks protection [1]. 
Patents are the most appropriate form of protection that is 
primarily encouraging for investors and biotechnologists. They 
can publicly present the results of the research, both through the 
 
1 Merril, Levin and Myers M., A patent System for the 21 st Century, Retrieved 
from: https://www.nap.edu/catalog/10976.html, date: 10. 11. 2016. 
possibility of publicly presenting the subject of 
biotechnological inventions and through the possibility of being 
rewarded. There is no other area with such a good relationship 
between patent protection and innovation incentives. The patent 
system plays an important role in fostering innovation, by 
providing legal protection to inventions and distributing useful 
information about them. Throughout its history, the patent 
system has had to adapt to new conditions. A series of judicial, 
legislative, administrative and diplomatic actions have 
influenced the extension of patent protection to new 
technologies (such as biotechnology) but also the emergence of 
new actors (such as universities and public research 
institutions)1.  
New technologies have weakened the traditional line 
between basic and applied research, enabling universities and 
other publicly funded research institutions to generate research 
results that qualify for patent protection. The results of such 
research may be further licensed. This is why patents are treated 
as "vehicles for transporting publicly funded research into 
innovative products and processes." 2 
II. ACADEMIC RESEARCH 
There is a clear increase in the number of academic patents 
protected primarily by biotechnological inventions, hence the 
Academic institutions have become “major players” in the 
patent arena. In the USA, for example, the number of patents 
granted to academic institutions has been steadily increasing. In 
the last decade, 50% of all patents in the field of natural sciences 
have been allocated to research centers at Universities. Europe 
is not far behind in terms of academic patents.  
For example, 75% of biotechnological patents were granted 
by the EPO (1985 to 1999) to Belgian universities. The number 
of Italian university patents has also increased. Patent activities 
at universities have tripled since the adoption of The Bayh Dole 
Act in the United States in 1980. It aimed to encourage the 
patenting of academic inventions.  
On the other hand, the university's cooperation with the 
private sector has increased through research funding, 
transferring intellectual property rights to license agreements 
and the creation of spinoff companies.  
2 Straus J. (2017): Intellectual property right and bioeconomy, Journal of 
Intellectual Property Law and Practice. 
Some experts have predicted that there will be challenges in 
the "interface" of biotechnology and innovation technologies 
and that these technologies will require the use of not only 
patent law, but also the copyright and rights of database 
manufacturers.3 
Many of the research in this area is still "basic" and is 
undertaken at universities financed partly by public funds. The 
cooperation with the private sector and the formation of public-
private partnerships are needed in order to utilize private 
funding for the aforementioned research [2]. It should also be 
emphasized that there is concern about the patenting effects of 
early-stage research results, its effects on further research and 
on the price of end products. This is important since the data 
indicate that a small number of universities with protected 
inventions also have high revenues, while the quality of patents 
at US universities is declining.4 
The Bayh Dole Act stipulates that institutions enter into 
contracts with inventors on the basis of which the inventors 
transfer the right to file a patent application to the institution 
concerned. The institution, on the other hand, grants a free 
license to the US Government to use the invention for its own 
purposes. The use of such inventions is especially intended for 
researchers whose research is funded by the US Government.5  
The development of biotechnology in the US has certainly 
been influenced by the increase in patenting and licensing of 
inventions by the University. In addition to the primary interest 
of the University, which is the scientific interest, there is 
increasing financial interest. One of the goals of the University, 
in addition to advancing scientific knowledge, is to make 
money. As a result, more and more Universities are seen as 
"services" rather than organizations, trying to make money on 
what they explored.6 
Since the first patent application for stem cells was filed in 
1989,in the UK, the number of patent applications has been 
steadily increasing. Universities are especially active, so almost 
half of the stem cell patents belong to Universities (42%), while 
the corporate sector holds 48%. Therefore, the University is 
now expected not only to engage in research and teaching. 
Knowledge sharing traditionally takes place through the 
publication of scientific papers in journals, conference 
presentations and the like [3]. But today, the Universities are 
also expected to make money from the knowledge produced, in 
order to primarily justify the investments made.7 
The Bayh Dole Act is often seen as a success of US official 
policy to facilitate the transfer of university research to 
industry, including universities to patent their inventions. 
As in the US, many countries, including European 
countries, have created their own way of financing university 
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research. The Lisbon Treaty stipulates that the EU aims to 
strengthen the scientific and technological basis for the 
achievement of a European Research Area, in which 
researchers disseminate scientific knowledge and technology 
freely, fostering industry competitiveness. 
In the biotechnology industry, for example, discoveries such 
as genetic cloning or mapping of the human genome, otherwise 
patented, have emerged as a result of research at universities. In 
the process, the knowledge that emerges from research at 
universities is "captured" and distributed through the patent 
system. 
Until a few years ago, there were many truths that were 
stable that patents could represent limited transferable 
knowledge. European universities and small research 
organizations are known for encouraging research so that they 
can focus on objective scientific work and on obtaining patents 
for their lives. This being the case, I will keep promoting 
government through patent rules as an important pre-emptive 
for knowledge transfer. Patents have been given equally 
important papers and scientific papers, especially when 
evaluated utilizing investigation and companionship and 
economics.  
The practice of combining patenting and publication is 
increasingly being used to allow researchers to benefit from 
both activities. In fact, they can harness the potential gains from 
patents and be recognized academically for the quality of their 
work.8 
One way of collaboration between academic researchers 
and the private sector is forming the spinoff companies. A 
subsidiary or spinoff company is a special form of an 
entrepreneurial company that was previously started and 
affiliated with another company. It was once a core company, 
which split off and became an independent company in the 
market. A special form of spinoff company is an academic 
spinoff company. It is defined as a company founded by a group 
of scientists. The main assets of these companies are patent-
protected inventions. Interest in the commercial application of 
knowledge created by universities is particularly pronounced in 
the field of biotechnology.9  
Thanks to these companies, university employees can be not 
only innovators or founders but also managers or directors of 
spinoff companies. It should be emphasized that even 
potentially market-successful innovations and well-developed 
regulations (regarding the establishment and operation of 
spinoff companies) do not guarantee the successful 
commercialization of research results. Particularly significant is 
the issue of financing these ventures. Large sums of money are 
often needed to ensure that innovation is brought to the market. 
6 Nelson R. (2001): Observations on the Post-Bayh Dole Rise of Patenting at 
American Universities, Journal of Technology Transfer, Kluver Academic 
Publisher, Netherland, no. 26, pp. 17. 
7Hescot L. A,13. 
8Do you do research? Think about patents, EPO,Retreived from: 
www.zis.gov.rs/upload/Publikacije/Lifleti/Bavite%20se%20istraživanjem.pdf,
date: 9.10.2016. 
9 Nielsen-Eric J., Aleksic-Stojanovic V., Nikolic J., “The role of entrepreneurial 
spin-offs in the economic development of Kragujevac, 193,Retreived from: 
https://ekjav.kg.ac.rs/sities/default/files/Zbornik, date: 12. 06.2017. 
Those sums are far greater than the financial capabilities of 
the company founders, and even of the university. It is, 
therefore, necessary to raise capital to finance innovative, high-
risk ventures.10 In the field of biotechnology, the use of patent 
pools is very important, both for the private and public sectors. 
A patent pool is an agreement between two or more holders of 
a patent right, on the basis of which they assign the right to the 
mutual use of the protected rights, or the right to use, jointly, to 
a third party. They are certainly useful because the companies 
can obtain licenses to use patent-protected technology from 
only one entity, thanks to a patent fund. Patent pools also 
eliminate patent blocking issues while reducing licensing costs.  
The patent pools eliminate the need for litigation because 
disputes can be solved or resolved through the creation of patent 
pools [4]. Small businesses that would not be able to withstand 
the costs of litigation, will more often “survive” and prosper if 
they are exempt from legal action in the future.  
The existence of patent pools allows interested parties to 
license all patents in the fund, which are necessary for the use 
of a particular technology, rather than requiring a license from 
each holder individually. Reducing transaction costs, as well as 
the ability to share R&D risks, are also important. We know that 
the university's primary mission is to deliver teaching and 
research. But today, universities are increasingly expected to 
make money from 'produced' knowledge, in order to justify 
investing in their research. Patenting research results enables 
the realization of research in the form of products. The patent 
system encourages research and development as well as 
technology transfer, all of which lead to economic development 
[5].  
III. PROJECT „HORIZON 2020“ 
Within the EU, the project “Horizon 2020” has been 
launched. It is the financial framework that implements“ the 
Innovation Union”, one of the key initiatives of the Europe 
2020 Strategy. The aim of the project is to ensure the 
development of science and technology, especially 
biotechnology at the world level. It is funded with € 80 billion 
(2014-2020). The aim of the project is removing all the 
obstacles to innovation and collaboration between the public 
and private sectors.11 The Agreement, provisionally applied 
from 1 January 2014, between the Government of the Republic 
of Serbia and the European Union on the participation of the 
Republic of Serbia in the EU Horizon 2020 - Framework 
Program for Research and Innovation (2014-2020), the 
Republic of Serbia was granted the status of an associated 
country.  
The Agreement entered into force in accordance with the 
Act Confirming that Agreement.12 Affiliate status means that 
all legal entities from that country have the same rights and 
obligations as legal entities from the EU Member States.13 
 
10 National Recommendations for Universities in Serbia for Managing 
Intellectual Property in Knowledge Transfer Activities, Belgrade, Retreived 
from: https://erasmusplus.rs/wp-content/uploads/2016/06/  
National Recommendations_web.pdf, date: 10.03.2018. 
11www.ec.europa.eu/horizont 2020, date: 15.09.2015. 
12Official Gazette of the RS-International Treaties ”, No 9/14 
The research commercialization enables the return of 
investment, which can be further invested in the new research. 
In this direction, a Project in Western Balkans was 
implemented. Five universities in the Western Balkans (from 
Kragujevac, Niš, Banja Luka, Podgorica, and Zenica), along 
with five European partners and five business incubators, in 
collaboration with the Intellectual Property Office, have 
developed an "Innovation Management Methodology". The 
purpose of the project is to help researchers and students, as a 
first step in the process of intellectual property 
commercialization. Thanks to partners with five incubators in 
the region, as well as developing collaboration with businesses, 
the best ideas will be supported in further market entry.14 
In Serbia, an agreement was signed between the Intellectual 
Property Office and the University of Belgrade (in June 
2013).On the basis of this agreement, the cooperation between 
the Intellectual Property Office and the Technology Transfer 
Center is being developed15, in the context of promoting the 
commercialization of intellectual property rights. Cooperation 
includes support in the enforcement of intellectual property 
rights as well as the promotion of cooperation between 
universities and the economy. Furthermore, this cooperation 
contributes to raising awareness of the importance of patents 
and other intellectual property rights in the technology transfer 
process. 
The modern technological revolution and its role as a key 
driver of social development have influenced not only the 
increasing importance of the protection of intellectual property 
rights but also the commercialization of them. 
IV. CONCLUSION 
The modern technological revolution and its role as a key 
driver of social development has influenced not only the 
increasing importance of the protection of intellectual property 
rights but also the commercialization of them. The financial 
aspect of biotechnology research and the lack of alternative 
investment protection imposes the need for their patent 
protection. In the past few years, biotechnological inventions 
have been constantly quoted in the 10 largest technical areas 
based on the number of patent applications filed with the 
European Patent Office (EPO). 
About half of these applications come from scientific 
institutes and universities. Therefore, it is necessary to establish 
a policy on teaching about intellectual property, then, it is 
necessary to establish cooperation between universities in the 
region in order to achieve common goals. More efforts are also 
needed to develop awareness of the importance of intellectual 
property teaching in higher education institutions, as university 
researchers, as noted, are increasingly using patents both as a 
measure of their own success and as a means of contributing to 
economic development. 
13 “Horizon 2020 Program ”, EIC Bulletin No.19, October 2014,1, 
14 „Innovation and cooperation with industry in the focus of the Western Balkan 
University“, EIC Bulletin, no.19, 2014, 2. 
15 With the joint cooperation of ZIS and the University of Belgrade, the Center 
for Transfer Technologies was established in Belgrade, by decision of the 
University Council on 26.10.2010. years. 
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